Columbia researchers found that a gene associated with an autoimmune form of hair loss could be activated to improve cancer immunotherapy.
Cell-based therapy expert Pawel Muranski, MD, discusses the challenges of testing cancer immunotherapy drugs in new patient groups.
Cancer immunotherapy drugs only work for a minority of patients, but a generic drug now used to increase blood flow may be able to improve those odds, a study by Columbia University Medical Center researchers suggests.
Immunotherapy expert Pawel Muranski speaks about the new CAR-T therapy for leukemia and his work to bring T cell therapies to patients with a wide range of cancers.
Prakash Satwani, MD, leads NYP/CUMC's program in CAR-T therapy, a new treatment that uses a patient's own T cells to attack cancer.
Bristol-Myers Squibb Company today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre have joined the International Immuno-Oncology Network.